Genomics and omics

Cancer genomics

8 papers and 17 abstracts co-authored by Raphael E. Szalat. Current lab members are shown in bold.

Papers 8

  1. 2026

    Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

    Aktas Samur A, Corre J, Talluri S, …, Szalat R, …, Samur MK

    Journal of Clinical Oncology44(4):321-334DOI: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaPubMed: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

  2. 2021

    Genetic Predictors of Mortality in Patients with Multiple Myeloma

    Hassan H, Szalat R

    The Application of Clinical GeneticsVolume 14:241-254DOI: Genetic Predictors of Mortality in Patients with Multiple MyelomaPubMed: Genetic Predictors of Mortality in Patients with Multiple Myeloma

  3. 2020

    Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

    Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

    Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

  4. 2019

    Genomic landscape and chronological reconstruction of driver events in multiple myeloma

    Maura F, Bolli N, Angelopoulos N, …, Szalat R, …, Campbell PJ

    Nature Communications10(1)DOI: Genomic landscape and chronological reconstruction of driver events in multiple myelomaPubMed: Genomic landscape and chronological reconstruction of driver events in multiple myeloma

  5. 2018

    A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan G

    Leukemia33(1):159-170DOI: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisPubMed: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  6. 2018

    Genomic patterns of progression in smoldering multiple myeloma

    Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

    Nature Communications9(1)DOI: Genomic patterns of progression in smoldering multiple myelomaPubMed: Genomic patterns of progression in smoldering multiple myeloma

  7. 2018

    Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan GJ

    Blood132(6):587-597DOI: Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaPubMed: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

  8. 2016

    Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

    Szalat R, Munshi NC

    American Society of Clinical Oncology Educational Booke442-e448DOI: Next-Generation Sequencing Informing Therapeutic Decisions and Personalized ApproachesPubMed: Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

Abstracts & posters 17

  1. 2020

    High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

    Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

    Blood136(Supplement 1):2-2DOI: High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

  2. 2019

    E2 ubiquitin conjugase UBE2T contributes to genome maintenance through homologous recombination in multiple myeloma

    Alagpulinsa D, Kumar S, Talluri S, …, Szalat R, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e139DOI: E2 ubiquitin conjugase UBE2T contributes to genome maintenance through homologous recombination in multiple myeloma

  3. 2019

    Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

    Szalat R, Lawlor M, Fulciniti M, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e8-e9DOI: Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

  4. 2019

    Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

    Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

    Blood134(Supplement_1):3089-3089DOI: Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

  5. 2019

    Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome

    Samur M, Samur A, Szalat R, …, Munshi N

    Clinical Lymphoma Myeloma and Leukemia19(10):e12-e13DOI: Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome

  6. 2019

    S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM

    Samur M, Szalat R, Aktas Samur A, …, Munshi N

    HemaSphere3(S1):11-12DOI: S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM

  7. 2019

    The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

    Samur MK, Aktas Samur A, Han T, …, Szalat R, …, Munshi NC

    Blood134(Supplement_1):3055-3055DOI: The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

  8. 2018

    Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications

    Bolli N, Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

    Haematologica103(S3):S51-S51

  9. 2018

    Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

    Samur MK, Chakraborty C, Szalat R, …, Munshi N

    Blood132(Supplement 1):190-190DOI: Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

  10. 2018

    The genomic landscape of structural variations and complex events in multiple myeloma

    Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

    Haematologica103(S3):S14-S14

  11. 2017

    Integrative Oncogenomic Analysis Combining Whole Genome, Transcriptome and Epigenome Identifies Altered Chromatin Accessibility Landscape in Multiple Myeloma

    Szalat R, Samur MK, Ott CJ, Lawlor M, Epstein C, Abraham BJ, Lin CY, et al.

    Blood130:328

  12. 2017

    The genomic landscape of multiple myeloma complex structural variations

    Maura F, Bolli N, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

    Blood, The Journal of the American Society of Hematology130(Suppl_1):330-330

  13. 2016

    A targeted sequencing approach in multiple myeloma reveals a complex landscape of genomic lesions that has implications for prognosis

    Bolli N, Biancon G, Gimondi S, Li Y, Sathiaseelan V, Maura F, Carniti C, et al.

    HAEMATOLOGICA101(Suppl. 1):160-160

  14. 2016

    Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

    Maura F, Bolli N, Minvielle S, …, Szalat R, …, Munshi N

    Blood128(22):116-116DOI: Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

  15. 2016

    Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

    Song XL, Szalat R, Talbot A, …, Bories JC

    Blood128(22):4462-4462DOI: Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

  16. 2016

    The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

    Szalat R, Bolli N, Maura F, …, Munshi NC

    Blood128(22):236-236DOI: The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

  17. 2016

    Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern

    Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

    Blood128(22):2088-2088DOI: Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern